Debiopharm
Switzerland - Lausanne
CDMO (Contract Manufacturing)Focus: Contract Development & Manufacturing
Debiopharm is a life sciences company focused on Contract Development & Manufacturing.
OncologyInfectious DiseasesEndocrinologyCardiovascularNephrology
Funding Stage
PRIVATE
Employees
1-50
Open Jobs
6
Pipeline & Clinical Trials
N/A
Clinical Trials (1)
NCT00423228Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease
N/AN/A
Clinical Trials (1)
NCT02022098Debio 1143-201 Dose-finding and Efficacy Phase I/II Trial
N/AUltrahypofractionated salvage radiotherapy to a local recurrence after radical prostatectomy
Recurrent Prostate CancerClinical Trials (1)
NCT05746806Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical Prostatectomy
N/ADebio 025
Chronic Hepatitis CClinical Trials (1)
NCT00854802A Study of Debio 025 (Alisporivir) Combined With Peg-IFNα2a and Ribavirin in Treatment naïve Chronic Hepatitis C Genotype 1 Patients
N/AAlisporivir
Hepatitis CClinical Trials (1)
NCT01970904Pharmacokinetics, Pharmacodynamics and Safety of DEB025 Plus Ribavirin in Chronic Hepatitis C Genotype 2 and 3 Treatment naïve Patients
N/ADebio 1453P
Healthy ParticipantsDebio 1450
Bacterial InfectionsClinical Trials (1)
NCT02162199A Single Dose Study of Debio 1450 in Healthy Subjects
Phase 1Debio 4126
AcromegalyClinical Trials (1)
NCT05364944A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
Phase 1Radiolabelled Xevinapant 200 mg
Healthy VolunteersClinical Trials (1)
NCT04962724A Study to Evaluate the Absorption, Metabolism, and Excretion and Absolute Bioavailability of Xevinapant in Healthy Male Participants
Phase 1Pembrolizumab
Adenocarcinoma of the PancreasPlacebo IV Solution
Bacterial InfectionsClinical Trials (1)
NCT02214433A Multiple Dose Study of Debio 1450 [Intravenous (IV) and Oral] in Healthy Volunteers
Phase 1Debio 0932
CancerClinical Trials (1)
NCT01168752Study of Debio 0932 in Patients With Advanced Solid Tumours or Lymphoma
Phase 1Istaroxime
Heart FailureClinical Trials (1)
NCT00869115Phase I Interaction Study of Istaroxime and Digoxin in Subjects With Stable Heart Failure
Phase 1Debio 0123
Advanced Solid TumorsClinical Trials (1)
NCT05109975A Study to Evaluate Safety and Preliminary Anti-tumor Activity of Debio 0123 as Monotherapy in Adult Participants With Advanced Solid Tumors
Phase 1Part A: Debio 1143
Solid TumorsClinical Trials (1)
NCT01930292Debio 1143 in Combination With Carboplatin and Paclitaxel in Patient With Advanced Solid Malignancies
Phase 1Alisporivir
Hepatic InsufficiencyClinical Trials (1)
NCT01860326Evaluate the Pharmacokinetics, Safety, and Tolerability of Alisporivir in Subjects With Hepatic Impairment Compared to Healthy Subjects
Phase 1[14C-pos 1]-Debio 1450 BES Solution
HealthyClinical Trials (1)
NCT02595203Mass Balance Recovery and Metabolic Profile of 14C Debio 1450 Following Single Oral and Intravenous Doses in Healthy Male Subjects
Phase 1Debio 1450
Bone Diseases, InfectiousClinical Trials (1)
NCT02726438Drug Penetration Into Bone After Repeated Oral Administration of Debio 1450 to Patients Undergoing Hip Replacement Surgery
Phase 1Alisporivir
Kidney Failure, ChronicClinical Trials (1)
NCT01975337Pharmacokinetics and Safety of Alisporivir in Subjects With End Stage Renal Disease on Hemodialysis Compared to Healthy Subjects
Phase 1Debio 1450
Healthy ParticipantsClinical Trials (1)
NCT03209648A Study to Investigate the Effect of Itraconazole on the Pharmacokinetics of Debio 1450 in Healthy Subjects
Phase 1Debio 1143
Carcinoma, Non-Small-Cell LungClinical Trials (1)
NCT03270176A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy
Phase 1Debio 1143
CancerClinical Trials (1)
NCT01078649Dose Escalation Study of Safety and Tolerability of AT-406 in Patients With Advanced Solid Tumors and Lymphomas
Phase 1Debio 0932
Non-small Cell Lung CancerClinical Trials (1)
NCT01714037A Clinical Study on the Safety and Efficacy of Debio 0932 in Combination With Standard of Care in Patients With Non-small Cell Lung Cancer [NSCLC]
Phase 1RP-6306
Advanced Solid TumorClinical Trials (1)
NCT05147350Study of RP-6306 With FOLFIRI in Advanced Solid Tumors
Phase 1RP-6306
Adult Solid TumorClinical Trials (1)
NCT05147272Study of RP-6306 With Gemcitabine in Advanced Solid Tumors
Phase 1Lunresertib
Advanced Solid TumorClinical Trials (1)
NCT04855656Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors
Phase 1Debio 0123
Advanced Solid TumorsClinical Trials (1)
NCT03968653Study of Oral Debio 0123 in Combination With Carboplatin in Participants With Advanced Solid Tumors
Phase 1Debio 0123
Small Cell Lung Cancer RecurrentClinical Trials (1)
NCT05815160Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy
Phase 1Debio1347
Solid TumoursClinical Trials (1)
NCT01948297Debio 1347-101 Phase I Trial in Advanced Solid Tumours With Fibroblast Growth Factor Receptor (FGFR) Alterations
Phase 1Debio 1562M
Acute Myeloid LeukemiaClinical Trials (1)
NCT06969430A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
Phase 1/2Fulvestrant
Breast CancerClinical Trials (1)
NCT03344536A Study of Debio 1347 Plus Fulvestrant in Patients With Metastatic Breast Cancer
Phase 1/2Debio 1143
Solid TumorClinical Trials (1)
NCT04122625Study to Assess Safety and Efficacy of the Second Mitochondrial-derived Activator of Caspases (SMAC) Mimetic Debio 1143
Phase 1/2Debio 0123 and Sacituzumab govitecan
Advanced Breast CancerPhase 1/2
Clinical Trials (1)
NCT05765812A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma
Phase 1/2Debio 4228
Prostate CancerClinical Trials (1)
NCT06395753A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
Phase 2Afabicin
Bone or Joint InfectionClinical Trials (1)
NCT03723551Study to Assess Safety, Tolerability and Efficacy of Afabicin in The Treatment of Participants With Bone or Joint Infection Due to Staphylococcus
Phase 2Alisporivir
Hepatitis CClinical Trials (1)
NCT01183169Efficacy and Safety of Adding Alisporivir (DEB025) to Peginterferon (IFN) Alfa-2a (Peg-IFN Alfa-2a) and Ribavirin in Chronic HCV Genotype 1 Patients Who Relapsed or Did Not Respond to Previous Treatment
Phase 2Alisporivir
SARS-CoV-2Clinical Trials (1)
NCT04608214Evaluation of Alisporivir for the Treatment of Hospitalised Patients With Infections Due to SARS-CoV-2 (COVID-19)
Phase 2Alisporivir
Hepatitis CClinical Trials (1)
NCT01215643Efficacy and Safety of Alisporivir Alone or Combined With RBV or PEG in Chronic Hepatitis C Genotype 2 and 3 Treatment-naïve Participants
Phase 2EPI-hNE4
FibrosisClinical Trials (1)
NCT00455767Safety and Efficacy Study of Depelestat in Acute Respiratory Distress Syndrome (ARDS) Patients
Phase 2Goserelin Acetate 3.6mg、Goserelin Acetate 10.8mg、Leuprolide Acetate 3.75mg、Leuprorelin Acetate 22.5mg、Triptorelin pamoate 11.25mg、Triptorelin pamoate 22.5mg
Triple Negative Breast CancerClinical Trials (1)
NCT06225284Neoadjuvant Chemotherapy With or Without GnRH Agonist for Premenopausal Triple-negative Early Breast Cancer Patients
Phase 2Alisporivir
Hepatitis CClinical Trials (1)
NCT02094443Alisporivir With RBV in Chronic Hepatitis C Genotype 2 and 3 Participants for Whom Interferon is Not an Option
Phase 2Debio 025
Chronic Hepatitis CClinical Trials (1)
NCT00537407A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment
Phase 2Istaroxime
Heart FailureClinical Trials (1)
NCT00838253Safety and Efficacy Study of Istaroxime in Acute Decompensated Heart Failure Patients
Phase 2Debio 1450 IV
Bacterial InfectionsClinical Trials (1)
NCT02426918Study of Debio 1450 for Bacterial Skin Infections
Phase 2Debio 1562
Diffuse Large B-Cell LymphomaClinical Trials (1)
NCT02564744Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL
Phase 2Debio 1347
Solid TumorClinical Trials (1)
NCT03834220Basket Trial in Solid Tumors Harboring a Fusion of FGFR1, FGFR2 or FGFR3- (FUZE Clinical Trial)
Phase 2Alisporivir
Hepatitis CClinical Trials (1)
NCT01500772Alisporivir With PEG and RBV in Protease Inhibitor (PI) Treatment Failure Patients With Chronic Hepatitis C
Phase 3Triptorelin
Central Precocious PubertyClinical Trials (1)
NCT01467882Efficacy, Safety, and Pharmacokinetics (PK) of Triptorelin 6-month Formulation in Patients With Central Precocious Puberty
Phase 3Alisporivir
Hepatitis CClinical Trials (1)
NCT02753699Long Term Follow-up Study to Assess Durability of Sustained Virologic Response in Alisporivir-treated Hepatitis C Patients
Phase 3Open Jobs (6)
P2605 - Legal & Pre-Commercial Alliance Coordinator
Lausanne, Vaud
Commercial1w ago
P2604 - Principal Clinical Pharmacologist
Lausanne, Vaud
Translational Medicine1mo ago
P2603 - Associate Safety Physician
Lausanne, Vaud
Clinical Safety & Pharmacovigilance1mo ago
Senior Analytical Project Manager
Martigny, Valais
Industrial Transposition2mo ago
P2522 - Intellectual Property Paralegal
Lausanne, Vaud (Hybrid)
Legal3mo ago
Candidature Spontanée - Martigny
Martigny, Valais
7y ago
Interview Prep Quick Facts
Portfolio: 47 clinical trials
Open Roles: 6 active jobs
Hiring Trend
Stable
6
Open Roles
+0
Added
-0
Filled/Removed
Based on last 4 crawl cycles